New York Times article, page-6

I think the 17/12/2020 US patent ann says a lot about the situation for this type of testing in the States and the other 18 countries where patents have been obtained. Seems like there will be increased demand globally for screening earlier (45) based on the US Preventative Services Task Force recommendation:
”The US represents one of the largest diagnostic markets in the world. The addition of a US patent sees Rhythm expand its global footprint and ultimately, access to a global addressable screening market of close to 800 ”million people. In the US, the current 50-74-year-old screening eligible population is ~94 million people. This market could grow in the short term by a further 21%, following the US Preventative Services Task Force recommendation that the colorectal cancer screening age be reduced, beginning at 45 years. As a result, where the expansion in the screening age group occurs in other markets, it is expected that the current global addressable market will also increase considerably.”